Aptose Biosciences Inc. (NASDAQ:APTO) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
Aptose has historically qualified as a foreign private issuer for purposes of reporting under the Securities Exchange Act of 1934 and filing registration statements under the Securities Act of 1933. Effective December 31, 2018, however, Aptose ceased qualifying as a foreign private issuer and is now required to file reports with the SEC as a domestic issuer. As a result of the Companys status change, Aptose is required to change the accounting standards in which it prepares its financial statements from IFRS to generally accepted accounting principles in the United States, or US GAAP.
In accordance with Canadian securities laws, the Company is required to reissue its unaudited condensed consolidated interim financial statements, prepared in accordance with US GAAP, for the three months ended March 31, 2018 and 2017, for the three and six months ended June 30, 2018 and for the three and nine months ended September 30, 2019. A copy of such financial statements are attached hereto as Exhibit 99.1, 99.2 and 99.3 and are incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
Aptose Biosciences Inc. Exhibit
EX-99.2 2 exh_991.htm Q2 Exhibit 99.1 Condensed Consolidated Interim Financial Statements (Unaudited) APTOSE BIOSCIENCES INC. Three and six months ended June 30,…
To view the full exhibit click
About Aptose Biosciences Inc. (NASDAQ:APTO)
Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company’s APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.